Phase Space Research

Plexus

PLXS · Investment summary · as of 20 August 2026

Priced slightly ahead of what the business has demonstrated

Portfolio decision
No position
Price · 20 August 2026
$242.53
12-month target
$219.48 -10%
Expected return
-9.5%
Next decision point
28 October 2026Results expected (estimated)

Business type: Cyclical · cyclical or commodity-sensitive

The business does not meet the quality standard for its economic type.

Investment view

At $242.53, PLXS requires a 24% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 4%.

The value rests on an exit multiple of 16.5x, a terminal operating margin of 4% and a 8.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: Programme-level concentration in a cycle downturn.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?Cyclical on the REVENUE leg, unusually stable on the MARGIN leg, and the hybrid is recorded rather than smoothed.
What do we forecast?Revenue growth of 4% demonstrated; a terminal operating margin of 4%; an exit multiple of 16.5x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is -19.3 percentage points.
What is it worth?Twelve-month target $219.48, -10% from the struck price. Scenario-weighted expected return net of costs -9.5%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

  1. By Date not announced — no test date is stated for this conditionIndustrial market-sector revenue grows at least 5% year-over-yearWhere it stands: Industrial net sales, YoY
  2. By Date not announced — no test date is stated for this conditionGross margin falls at or above 9.5% for two consecutive quartersWhere it stands: quarterly gross margin
  3. By Date not announced — no test date is stated for this conditionNet working capital no more than 21% of trailing revenueWhere it stands: NWC / TTM revenue

Catalysts and falsifiers

Date or windowEventThesis confirmed ifThesis weakened or refuted if
28 October 2026Next results (date estimated, not issuer-confirmed)Revenue and margin in line with, or above, the house pathA miss that moves the full-year path below the guided floor

Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.

Risk and sell discipline

Impairment case

Programme-level concentration in a cycle downturn. PLXS's growth is ramp-driven: the Q3 FY2026 10-Q attributes +$107.4mn of AMER's +$116.0mn quarterly increase to production ramps of new products for EXISTING customers. Those ramps are cancellable programmes, not contracted backlog -- PLXS discloses no backlog figure, no take-or-pay and no contracted duration. The permanent-loss case is a simultaneous industrial/semicap capex pause and one or more programme cancellations, in which revenue reverts toward the FY2024 level of $3,960.8mn while the $1,488.4mn inventory position and $895.7mn of net working capital are written down or unwound at a loss.

Estimated probability 20%. No loss magnitude is on file, so the level at which the position would be resized cannot be struck and this case cannot be monitored against a loss budget.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $202.35 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

Not applicable as an open position: no position is proposed. On approach to the $219.48 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 12% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityNot metIs the business worth owning under its declared economic type?
ValuationNot metIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetProgramme-level concentration in a cycle downturn.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The gap between what today's price requires and what the business has demonstrated is -19.3 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: programme-level concentration in a cycle downturn. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $202.35, which forces an immediate review.